Trial Profile
RTOG 0617: A Randomized Phase III Comparison of Standard-Dose (60Gy) versus High-Dose (74Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND 103444) In Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 16 Dec 2019 Results assessing long-term results published in the Journal of Clinical Oncology
- 05 Jun 2018 Results of a secondary analysis (n=469) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.